Tiago Torres
YOU?
Author Swipe
View article: Short-Term Efficacy of Lebrikizumab Versus Dupilumab in Combination with Topical Corticosteroids in Adults with Moderate-to-Severe Atopic Dermatitis: Matching-Adjusted Indirect Comparison
Short-Term Efficacy of Lebrikizumab Versus Dupilumab in Combination with Topical Corticosteroids in Adults with Moderate-to-Severe Atopic Dermatitis: Matching-Adjusted Indirect Comparison Open
Lebrikizumab plus TCS was comparable to dupilumab plus TCS across all efficacy endpoints at week 16.
View article: Addiction and chronic skin diseases: A Pan‐European study on prevalence, associations and patient impact
Addiction and chronic skin diseases: A Pan‐European study on prevalence, associations and patient impact Open
Background Chronic skin diseases such as psoriasis (PSO), atopic dermatitis (AD) and hidradenitis suppurativa (HS) are frequently associated with psychological distress, potentially promoting maladaptive coping mechanisms including addicti…
View article: Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis Open
Comparable maintenance of efficacy was observed between tralokinumab and lebrikizumab after 52 weeks of treatment among patients meeting response criteria at week 16.
View article: JAK inhibitors for the treatment of palmoplantar pustulosis: a narrative review
JAK inhibitors for the treatment of palmoplantar pustulosis: a narrative review Open
JAK inhibitors show promise as a novel therapeutic option for PPP, given their ability to modulate multiple inflammatory pathways. Although current evidence is limited to case series and reports, results are encouraging and warrant confirm…
View article: Nemolizumab for the treatment of atopic dermatitis
Nemolizumab for the treatment of atopic dermatitis Open
IL-31 plays a critical role in the pathogenesis of atopic dermatitis. Findings from clinical trials support the efficacy and safety of nemolizumab in the treatment of moderate-to-severe AD.
View article: Preserving joint line orientation in TKA improves short‐ to mid‐term outcomes: A systematic review and meta‐analysis
Preserving joint line orientation in TKA improves short‐ to mid‐term outcomes: A systematic review and meta‐analysis Open
Purpose Joint line orientation (JLO) has been identified as a potential factor influencing clinical outcomes following total knee arthroplasty (TKA). This systematic review and meta‐analysis aimed to assess whether preserving the JLO accor…
View article: Treatment of vitiligo with topical ruxolitinib: a narrative review
Treatment of vitiligo with topical ruxolitinib: a narrative review Open
Vitiligo is a chronic autoimmune disorder characterized by the selective destruction of melanocytes, leading to depigmented patches of skin. Whilst its pathogenesis is not fully understood, genetic predisposition, environmental triggers, o…
View article: Optimizing Psoriasis Treatment with Tildrakizumab: Current Evidence and Expert Recommendations for Treatment Individualization in Clinical Practice
Optimizing Psoriasis Treatment with Tildrakizumab: Current Evidence and Expert Recommendations for Treatment Individualization in Clinical Practice Open
Psoriasis is a chronic immune-driven inflammatory condition that affects millions of people worldwide. Biologics appeared in the recent years to offer an effective treatment for moderate-to-severe plaque psoriasis. Their efficacy, however,…
View article: Celebrating milestones and embracing innovation: the next chapter for Drugs in Context
Celebrating milestones and embracing innovation: the next chapter for Drugs in Context Open
The Senior Editors of Drugs in Context are excited to announce that the journal received its first Impact Factor of 2.8 in the 2025 Edition of Journal Citation Reports1 by Clarivate. This represents a significant metric milestone, and the …
View article: International Psoriasis Council psoriasis disease severity reclassification: Update on validity, acceptance, and implementation
International Psoriasis Council psoriasis disease severity reclassification: Update on validity, acceptance, and implementation Open
Contains fulltext : 324605.pdf (Publisher’s version ) (Open Access)
View article: Effectiveness and Safety of Adalimumab Biosimilars in Pediatric Psoriasis: A Multi-Center International Experience
Effectiveness and Safety of Adalimumab Biosimilars in Pediatric Psoriasis: A Multi-Center International Experience Open
Adalimumab biosimilars showed a favorable effectiveness/safety profile in childhood psoriasis. Switching from reference adalimumab to biosimilars did not impact effectiveness and safety. A likelihood of discontinuation was noted in patient…
View article: Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis
Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis Open
Deucravacitinib was significantly more effective than placebo in the 52-week, phase III POETYK PSO-1 and PSO-2 trials. This study further evaluated deucravacitinib efficacy compared with placebo in these trials based on Psoriasis Area and …
View article: Update on Generalized Pustular Psoriasis
Update on Generalized Pustular Psoriasis Open
Generalized pustular psoriasis (GPP) is a rare but severe inflammatory skin disease characterized by the eruption of widespread sterile pustules, often accompanied by systemic inflammation. Although GPP can coexist with plaque psoriasis, i…
View article: Multidimensional Burden of Moderate-to-Severe Atopic Dermatitis in Adolescent and Adult Patients from Portugal and Greece: Results from the Global Cross-Sectional Study MEASURE-AD
Multidimensional Burden of Moderate-to-Severe Atopic Dermatitis in Adolescent and Adult Patients from Portugal and Greece: Results from the Global Cross-Sectional Study MEASURE-AD Open
Understanding and recognizing the complex burden of moderate-to-severe AD is required to encourage and guide changes in public policy for the effective management of patients.
View article: Assessment of competencies of clinical research professionals and proposals to improve clinical research in Portugal
Assessment of competencies of clinical research professionals and proposals to improve clinical research in Portugal Open
Background Clinical studies are coordinated by multidisciplinary teams, which often lack adequate training and competencies. In this study, ROCHE and AICIB (Agency for Clinical Research and Biomedical Innovation) conducted a self-assessmen…
View article: Real-world experience with brodalumab in a Portuguese cohort of patients with moderate-to-severe psoriasis
Real-world experience with brodalumab in a Portuguese cohort of patients with moderate-to-severe psoriasis Open
This real-world data show that brodalumab is effective and safe for the treatment of moderate-to- severe psoriasis.
View article: Interleukin-4 and Atopic Dermatitis: Why Does it Matter? A Narrative Review
Interleukin-4 and Atopic Dermatitis: Why Does it Matter? A Narrative Review Open
Atopic dermatitis (AD) is a common chronic inflammatory skin condition that significantly impairs patients' quality of life as a result of intense itching and persistent eczematous lesions. Although AD has a multifaceted etiology-including…
View article: Minimally invasive solutions for ischiofemoral impingement: case analysis and evolving surgical strategies
Minimally invasive solutions for ischiofemoral impingement: case analysis and evolving surgical strategies Open
Variations in the femoral version are increasingly recognized as a cause of coxalgia due to impingement or instability. The true prevalence of these variations remains unknown. The authors report a case of bilateral ischiofemoral impingeme…
View article: Portuguese consensus on first line treatment of moderate-to-severe psoriasis with a non-TNF inhibitor therapy – a delphi methodology
Portuguese consensus on first line treatment of moderate-to-severe psoriasis with a non-TNF inhibitor therapy – a delphi methodology Open
Given the existence of various risks associated with TNFi usage, this clinical perspective overview of Portuguese experts in PsO treatment emphasizes the need for a tailored therapeutic framework in the management of PsO.
View article: Long‐Term Real‐World Safety Profile of Secukinumab Assessed Through a 9‐Year Experience in Patients Affected by Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Results From a Multicentric Retrospective Study
Long‐Term Real‐World Safety Profile of Secukinumab Assessed Through a 9‐Year Experience in Patients Affected by Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Results From a Multicentric Retrospective Study Open
Secukinumab is a biologic agent known for its durable efficacy in chronic plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Monitoring the safety of secukinumab is a priority to ensure its long‐term usage. …